To the Editor:

I read with interest the recently published article by Lumlertgul *et al.* regarding secondary oxalate nephropathy.[@bib1] In this systematic review, the authors describe causes and outcomes of oxalate nephropathy by gathering data from case reports and case series. Unfortunately, the authors chose to restrict the literature search to exposure of more than 30 days before the diagnosis. In doing so, the authors missed the impact of short-term drug exposure. We recently described that hydroxocobalamin (Cyanokit, Merck Santé SAS) is associated with oxaluria and oxalate nephropathy.[@bib2] Cyanokit is approved by the Food and Drug Administration for the treatment of cyanide poisoning. Hydroxocobalamin chelates cyanide to form cyanocobalamin, which is excreted by the kidneys. My colleagues and I described two cases of biopsy-proven oxalate nephropathy after exposure to Cyanokit.[@bib2] Both patients presented with severe acute kidney injury (AKI). Furthermore, in a cohort of burn patients, the use of Cyanokit was significantly associated with the risk of AKI, even after adjustment for potential confounding factors. Oxaluria was also reported in healthy volunteers and animals receiving hydroxocobalamin.[@bib3] To conclude, nephrologists and intensivists caring for patients with AKI should be aware of the risk of oxalate nephropathy even after short-term exposure to drugs such as hydroxocobalamin. Detection of oxaluria can easily orient the diagnosis.
